Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
Yoichiro Yoshida, Takeshi Yamada, Hirohiko Kamiyama, Chihiro Kosugi, Keiichiro Ishibashi, Hiroshi Yoshida, Hideyuki Ishida, Satoru Yamaguchi, Hidekazu Kuramochi, A. Fukazawa, Hiromichi Sonoda, Kazuhiko Yoshimatsu, Akihisa Matsuda, Suguru Hasegawa, Kazuhiro Sakamoto, Toshiaki Otsuka, Keiji Koda, On behalf of the TAS CC3 Study Group.
Topics & Concepts
MedicineBevacizumabIrinotecanClinical endpointInternal medicineNeutropeniaOxaliplatinAdverse effectColorectal cancerProgression-free survivalPhases of clinical researchOncologyFebrile neutropeniaSurgical oncologyLeukopeniaSurgeryClinical trialChemotherapyCancerColorectal Cancer Treatments and StudiesCancer Research and TreatmentsColorectal Cancer Surgical Treatments